...
search icon
arqt-img

Arcutis Biotherapeutics Inc, Common Stock

ARQT

NSQ

$13.42

+$0.43

(3.31%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.57B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.66M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.99 L
$16.2 H
$13.42

About Arcutis Biotherapeutics Inc, Common Stock

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARQTSectorS&P500
1-Week Return9.02%0.54%0.54%
1-Month Return2.6%3.28%1.66%
3-Month Return31.83%3.01%3.83%
6-Month Return59.38%-4.69%9.77%
1-Year Return41.56%1.41%23.47%
3-Year Return-16.18%15.72%42.73%
5-Year Return-50.11%42.38%82.01%
10-Year Return-38.44%103.91%190.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue---3.69M59.61M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":6.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue195.00K455.00K763.00K754.00K4.99M[{"date":"2019-12-31","value":3.91,"profit":true},{"date":"2020-12-31","value":9.12,"profit":true},{"date":"2021-12-31","value":15.3,"profit":true},{"date":"2022-12-31","value":15.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(195.00K)(455.00K)(763.00K)2.93M54.62M[{"date":"2019-12-31","value":-0.36,"profit":false},{"date":"2020-12-31","value":-0.83,"profit":false},{"date":"2021-12-31","value":-1.4,"profit":false},{"date":"2022-12-31","value":5.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)79.54%91.63%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":86.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses43.13M136.65M206.53M304.56M295.72M[{"date":"2019-12-31","value":14.16,"profit":true},{"date":"2020-12-31","value":44.87,"profit":true},{"date":"2021-12-31","value":67.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.1,"profit":true}]
Operating Income(43.13M)(136.65M)(206.53M)(301.63M)(241.10M)[{"date":"2019-12-31","value":-4313200000,"profit":false},{"date":"2020-12-31","value":-13664500000,"profit":false},{"date":"2021-12-31","value":-20652900000,"profit":false},{"date":"2022-12-31","value":-30162700000,"profit":false},{"date":"2023-12-31","value":-24110100000,"profit":false}]
Total Non-Operating Income/Expense-967.00K173.00K(25.48M)(46.79M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":17.89,"profit":true},{"date":"2022-12-31","value":-2635.26,"profit":false},{"date":"2023-12-31","value":-4838.78,"profit":false}]
Pre-Tax Income(42.00M)(135.68M)(206.36M)(311.46M)(259.03M)[{"date":"2019-12-31","value":-4199600000,"profit":false},{"date":"2020-12-31","value":-13567800000,"profit":false},{"date":"2021-12-31","value":-20635600000,"profit":false},{"date":"2022-12-31","value":-31145800000,"profit":false},{"date":"2023-12-31","value":-25902700000,"profit":false}]
Income Taxes(1.14M)(84.30K)(454.00K)9.83M3.11M[{"date":"2019-12-31","value":-11.56,"profit":false},{"date":"2020-12-31","value":-0.86,"profit":false},{"date":"2021-12-31","value":-4.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":31.67,"profit":true}]
Income After Taxes-(135.59M)(205.90M)(321.29M)(262.14M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-13559370300,"profit":false},{"date":"2021-12-31","value":-20590200000,"profit":false},{"date":"2022-12-31","value":-32128900000,"profit":false},{"date":"2023-12-31","value":-26214000000,"profit":false}]
Income From Continuous Operations(42.00M)(135.68M)(206.36M)(311.46M)(267.88M)[{"date":"2019-12-31","value":-4199600000,"profit":false},{"date":"2020-12-31","value":-13567800000,"profit":false},{"date":"2021-12-31","value":-20635600000,"profit":false},{"date":"2022-12-31","value":-31145800000,"profit":false},{"date":"2023-12-31","value":-26787500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(42.00M)(135.68M)(205.90M)(321.29M)(262.14M)[{"date":"2019-12-31","value":-4199600000,"profit":false},{"date":"2020-12-31","value":-13567800000,"profit":false},{"date":"2021-12-31","value":-20590200000,"profit":false},{"date":"2022-12-31","value":-32128900000,"profit":false},{"date":"2023-12-31","value":-26214000000,"profit":false}]
EPS (Diluted)(13.95)(3.89)(4.16)(5.65)(3.92)[{"date":"2019-12-31","value":-1395,"profit":false},{"date":"2020-12-31","value":-389,"profit":false},{"date":"2021-12-31","value":-416,"profit":false},{"date":"2022-12-31","value":-565,"profit":false},{"date":"2023-12-31","value":-392,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARQT
Cash Ratio 1.92
Current Ratio 2.46
Quick Ratio 2.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARQT
ROA (LTM) -31.14%
ROE (LTM) -192.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARQT
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARQT
Trailing PE NM
Forward PE NM
P/S (TTM) 10.96
P/B 9.35
Price/FCF NM
EV/R 9.67
EV/Ebitda NM

FAQs

What is Arcutis Biotherapeutics Inc share price today?

Arcutis Biotherapeutics Inc (ARQT) share price today is $13.42

Can Indians buy Arcutis Biotherapeutics Inc shares?

Yes, Indians can buy shares of Arcutis Biotherapeutics Inc (ARQT) on Vested. To buy Arcutis Biotherapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARQT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arcutis Biotherapeutics Inc be purchased?

Yes, you can purchase fractional shares of Arcutis Biotherapeutics Inc (ARQT) via the Vested app. You can start investing in Arcutis Biotherapeutics Inc (ARQT) with a minimum investment of $1.

How to invest in Arcutis Biotherapeutics Inc shares from India?

You can invest in shares of Arcutis Biotherapeutics Inc (ARQT) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARQT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arcutis Biotherapeutics Inc shares
What is Arcutis Biotherapeutics Inc 52-week high and low stock price?

The 52-week high price of Arcutis Biotherapeutics Inc (ARQT) is $16.2. The 52-week low price of Arcutis Biotherapeutics Inc (ARQT) is $6.99.

What is Arcutis Biotherapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arcutis Biotherapeutics Inc (ARQT) is 9.35

What is the Market Cap of Arcutis Biotherapeutics Inc?

The market capitalization of Arcutis Biotherapeutics Inc (ARQT) is $1.57B

What is Arcutis Biotherapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Arcutis Biotherapeutics Inc is ARQT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top